Clinical Trial Update: BGJ398 for the Treatment of Tumor-Induced Osteomalacia [Phase 2]

View source ↗

Summary

Phase 2 trial of BGJ398 for tumor-induced osteomalacia was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oncogenic Osteomalacia
• Tumor-induced Osteomalacia

Drugs mentioned

• BGJ398 (BGJ398)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Tumor-Induced Osteomalacia, Oncogenic Osteomalacia | Phase 2 | Status: TERMINATED | Results posted: 2021-04-08